Table 3.
| Study | The 1860- Lira DPP-4 study (52 weeks) | DURATION 2 (26 weeks) - Add on therapy to Metformin | DURATION 4 (26 weeks) - Monotherapy | ||||
|---|---|---|---|---|---|---|---|
| Agent | Liraglutide .8 mg/day | Liraglutide1.2 mg/day | Sitagliptin100 mg/day | Exenatide QW2 mg/weekly | Sitagliptin100 mg/day | Exenatide QW2 mg/weekly | Sitagliptin100 mg/day |
| Number of patients | 225 | 221 | 219 | 160 | 166 | 248 | 163 |
| Mean baseline HbA1c (%) | 8.4 (0.8) | 8.4 (0.7) | 8.5 (0.7) | 8.6 (1.2) | 8.5 (1.2) | 8.4-8.6 | 8.4-8.6 |
| Change in HbA1c (%) | -1.51 | -1.29 | -0.88 | -1.5 | -0.9 | -1.53 | -1.15 (P =<0.001) |
| Mean treatment difference in HbA1c with DPP-4 inhibitor | -0.63 (P <0.0001) |
-0.4 (P <0.0001) |
- | -0.6 (P <0.0001) |
- | - | - |
| Mean baseline FPG (mmol/L) |
10.1 (2.4) | 9.9(2.4) | 10.0 (2.0) | 9.2(2.9) | 9.1(2.5) | 9.7 to 9.9 | 9.7 to 9.9 |
| Change in FPG (mmol/L) |
-2.04 | -1.71 | -0.59 | -1.8 | -0.9 | -2.3 | -1.1 (P =<0.001) |
| Mean treatment difference in FPG with DPP-4 inhibitor | -1.45 (P <0.0001) |
-1.13 (P <0.0001) |
- | -0.9 (P <0.0001) |
- | - | - |
| Baseline weight (Kg) | 93.7(18.4) | 94.6(18.1) | 93.1(18.9) | 89(20) | 87(20) | 85.9 to 88.6 | 85.9 to 88.6 |
| Change in weight (Kg) | -3.68 | -2.78 | -1.16 | -2.3 | -0.8 | -2.0 | -0.8 (P <0.001) |
| Mean treatment differences in weight with DPP-4 inhibitor | -2.53 (P <0.0001) |
-1.62 (P <0.0001) |
- | -1.5 (P <0.0001) |
- | - | - |
| Incidence of hypoglycemia | 0.143episodes/ patient/year |
0.154 episodes/ patient/year |
0.137 episodes/ patient/year |
1% | 3% | 5.2% | 3.1% |
| Nausea Number (%) | 60 (27.5) | 40 (21.7) | 12 (5.5) | 38 (24) | 16 (10) | 11.3% | 3.7% |
| Diarrhea Number (%) | 27 (12.4) | 20 (9) | 14 (6.4) | 29 (18) | 16 (10) | 10.9% | 5.5% |
DDP-4, dipeptidyl peptidase 4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; HbA1c, hemoglobulin A1c